Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 1/20 | 0.44 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297608 | 0.92 | CCR5 (0.43) | ENPP2LMNASCN9A | |
| SCHEMBL3591327 | 0.92 | ENPP2 (0.41) | TRPC3TRPC7ENPP2LMNAMAPT | |
| SCHEMBL3587524 | 0.91 | MDM2 (0.39) | TRPC3TRPC7ENPP2LMNAMAPT | |
| SCHEMBL3593203 | 0.91 | CPT1A (0.44) | ENPP2SCN9A | |
| SCHEMBL3588590 | 0.90 | L3MBTL1 (0.43) | TRPC3TRPC7ENPP2LMNAMAPT | |
| SCHEMBL3590006 | 0.89 | ENPP2 (0.43) | TRPC3ENPP2LMNAMAPTFAAH | |
| SCHEMBL3580394 | 0.88 | TRPC3 (0.44) | TRPC3TRPC7ENPP2LMNAMAPT | |
| SCHEMBL3587938 | 0.88 | GRIN2B (0.40) | TRPC3TRPC7ENPP2LMNA | |
| SCHEMBL3583534 | 0.85 | ALDH1A1 (0.40) | NPSR1SCN9A | |
| SCHEMBL3590433 | 0.84 | TRPC3 (0.40) | TRPC3TRPC7LMNAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | TRPC3 176/4885TRPC7 350/4885ENPP2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.